Oral Iron Strategies Enter Trial Ground in Pediatric Crohn’s Anemia
Children and young adults with Crohn’s disease often carry a second burden beyond intestinal inflammation: iron deficiency anemia. In this phase 4 trial, investigators at Weill Medical College of Cornell University are testing whether the way iron is given can improve laboratory recovery and help clarify which approach fits this population best. The study is recruiting now under ClinicalTrials.gov ID NCT07925450, with an estimated enrollment of 150 participants ages 3 to 21 years.
The trial does not ask whether iron matters. It asks how iron should be delivered when the gut is already compromised by chronic inflammatory disease and mucosal injury.
Why Iron Repletion Is Harder in Crohn’s Disease
Pediatric Crohn’s disease can disrupt iron balance through several overlapping mechanisms. Reduced intake, impaired absorption, chronic inflammation, and occult blood loss all push hemoglobin and iron stores downward. In children and adolescents, the consequences can be felt quickly: fatigue, reduced activity tolerance, poor concentration, and lower overall wellbeing. Those symptoms can persist even when bowel inflammation is otherwise quiet, which is why the study restricts enrollment to participants with quiescent Crohn’s disease assessed by histopathology, CRP, ESR, and Pediatric Crohn’s Disease Activity Index scores.
That design choice is clinically important. It separates anemia management from active inflammatory flare, making it easier to examine whether iron dosing itself influences hematologic recovery rather than simply reflecting control of intestinal disease.
Three Iron Paths, One Comparative Framework
Investigators are using a randomized, parallel-assignment design with no masking. Participants enter one of three arms. The first receives standard-care daily oral iron at 3 to 6 mg/kg per day. The second receives low-dose oral iron every other day at 1 to 2 mg/kg. The third is a physician-directed arm, allowing the treating clinician to select the dose, schedule, and formulation when neither protocol-defined regimen is judged appropriate.
Daily oral iron has long been a default treatment, but iron absorption is not a passive process. Hepcidin biology offers a plausible reason why less frequent dosing may be advantageous in some patients: oral iron can acutely increase hepcidin, which then suppresses subsequent absorption for a period of time. A lower-frequency strategy may therefore preserve uptake while limiting gastrointestinal intolerance, though this trial is designed to measure outcomes rather than assume the answer.
The use of a physician-directed comparator adds real-world texture. In pediatric practice, one-size-fits-all iron replacement often fails because disease burden, tolerance, and prior response vary widely from child to child.
Hemoglobin, MCV, and Iron Stores Will Be Tracked Over Time
The primary outcomes center on routine-care laboratory data rather than a narrow bespoke endpoint. Median hemoglobin level will be followed at routine visits typically every 4 to 12 weeks for up to three years after enrollment, with age- and sex-specific reference ranges used for interpretation. Median mean corpuscular volume, or MCV, will be tracked on the same cadence, and normalization is defined in the protocol as MCV greater than 80 fL. Serum iron, iron saturation, and ferritin will be measured approximately every six months during follow-up.
The structure of those endpoints reflects clinical reality. Hemoglobin can recover before iron stores are fully replenished, while ferritin and iron saturation provide a wider view of whether replacement has truly restored reserve. MCV adds another dimension, particularly in microcytic anemia, where red cell size can remain depressed until iron availability improves enough to support normal erythropoiesis.
A single laboratory value rarely tells the full story in Crohn’s disease. The pace of recovery across hemoglobin, ferritin, and MCV may reveal whether one dosing pattern restores iron balance more efficiently than another.
Symptoms, Remission, and Fatigue Matter at the Bedside
Secondary outcomes extend beyond laboratory correction. The proportion of participants in clinical remission will be assessed using the Pediatric Crohn’s Disease Activity Index definition of 0 to 10. General wellbeing, also captured through the PCDAI framework, will be reported as a median score and interquartile range by arm at each assessment point. Investigators will also document the number of participants with fatigue as an adverse event over the course of follow-up.
Those measures matter because anemia is not merely a number on a complete blood count. In a child with Crohn’s disease, fatigue can limit school attendance, sports participation, and day-to-day resilience long before a clinician sees a dramatic hematologic change. By collecting symptom data alongside laboratory values, the study is positioned to examine whether biochemical correction aligns with how patients actually feel.
Eligibility Focuses on a Narrow, Clinically Specific Population
Enrollment is limited to male and female participants ages 3 to 21 years with biopsy-confirmed Crohn’s disease involving gastric, duodenal, or jejunal mucosa and concurrent iron deficiency anemia. The protocol excludes participants who received antibiotics within six weeks of endoscopic evaluation. Healthy volunteers are not eligible.
That inclusion pattern suggests a deliberately focused attempt to study small-bowel disease in a setting where oral iron handling may be especially challenging. The upper gastrointestinal and proximal small intestinal involvement described in the criteria could influence absorption, making the question of dose scheduling more than a theoretical exercise.
The study started on September 13, 2023, with estimated primary completion in March 2029 and final completion in June 2029. The long follow-up window should allow repeated assessment of response patterns across childhood and adolescence, periods when iron requirements and growth demands can change quickly.
What This Trial Could Clarify for Pediatric Practice
If one oral iron strategy produces steadier gains in hemoglobin, MCV, and iron stores, pediatric gastroenterologists may gain a more evidence-based path for treating a complication that is often managed empirically. If symptom burden tracks better with one approach than another, the trial could also help sharpen treatment decisions beyond laboratory normalization alone.
The physician-directed arm may prove especially revealing. Real-world prescribing often diverges from protocolized daily dosing because of nausea, constipation, poor adherence, prior treatment failure, or concern that standard oral iron will not be tolerated. Observing how those individualized choices perform alongside randomized daily and every-other-day regimens may help define where clinical judgment still outperforms fixed dosing.
The study remains in progress, and no results are posted yet. Its value will depend on whether the laboratory signals and symptom outcomes separate cleanly enough to guide day-to-day decisions in a population where anemia is common, absorption is uncertain, and treatment tolerance can be fragile.